| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00007890-199612270-00009 |
| P698 | PubMed publication ID | 8990355 |
| P50 | author | Philip F Halloran | Q40000948 |
| P2093 | author name string | D Russell | |
| L Paul | |||
| J Jeffery | |||
| E Cole | |||
| A Shoker | |||
| C Stiller | |||
| A Boucher | |||
| J Lawen | |||
| R Dandavino | |||
| P Daloze | |||
| N Muirhead | |||
| P Belitsky | |||
| D Rush | |||
| R Loertscher | |||
| P Parfrey | |||
| P Keown | |||
| D Landsberg | |||
| J Zaltzman | |||
| P Handa | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cyclosporine | Q367700 |
| P304 | page(s) | 1744-1752 | |
| P577 | publication date | 1996-12-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group | |
| P478 | volume | 62 |
| Q43705339 | A limited sampling strategy for cyclosporine area under the curve monitoring in lung transplant recipients. |
| Q44136543 | A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients |
| Q77725007 | A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral |
| Q35177677 | A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Berlin, Germany, November 19, 2001. |
| Q44146556 | Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling |
| Q44971336 | An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation |
| Q46554256 | Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: insights from the Mycophenolate Steroid-Sparing Trial. |
| Q44568274 | C0/C2 cyclosporine levels monitoring in renal transplantation |
| Q35711246 | Cardiac transplant experience with cyclosporine |
| Q35826755 | Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. |
| Q77176309 | Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year |
| Q44491043 | Comparison of peak and trough level monitoring of cyclosporine treatment using two modern cyclosporine preparations. |
| Q73040136 | Comparison of predose vs 2-h postdose blood metabolites/cyclosporine ratios in kidney and liver transplant patients |
| Q43929552 | Comparison of renal transplant outcome with Neoral versus Sandimmune as part of an initial triple therapy regimen |
| Q34494584 | Contemporary immunosuppression in renal transplantation |
| Q77891569 | Conversion from Sandimmune to Neoral in stable pediatric liver transplant recipients |
| Q77632865 | Conversion to Sandimmun Neoral in stable renal transplant recipients over 1 year: hepatitis, liver dysfunction, dosing intervals, and therapeutic ranges |
| Q73194059 | Current opinions on therapeutic drug monitoring of immunosuppressive drugs |
| Q34439272 | Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation |
| Q61764257 | Cyclosporine A monitoring ? how to account for twice and three times daily dosing |
| Q77369580 | Cyclosporine A: peak or trough level monitoring in renal transplant recipients? |
| Q52956147 | Cyclosporine absorption profiling and therapeutic drug monitoring using C(2) blood levels in stable renal allograft recipients. |
| Q77176290 | Cyclosporine heart transplantation |
| Q74686117 | Cyclosporine peak levels provide a better correlation with the area-under-the-curve than trough levels in liver transplant patients treated with neoral |
| Q34360395 | Cyclosporine therapeutic drug monitoring |
| Q77175909 | Cyclosporine: the principal immunosuppressant for renal transplantation |
| Q43828419 | Decreasing side effects of Neoral through three-times-a-day protocol in Chinese renal transplant patients |
| Q46221600 | Disposition of cyclosporine after intravenous and multi-dose oral administration in cats |
| Q44256939 | Evaluation of different sampling times for best prediction of cyclosporine area under the curve in renal transplant recipients |
| Q77175885 | Evaluation of the safety and tolerability of Neoral and Sandimmune: a meta-analysis |
| Q35711382 | Evolution of the therapeutic drug monitoring of cyclosporine |
| Q35711395 | Experience with therapeutic drug monitoring of cyclosporine |
| Q35711423 | History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion |
| Q44419233 | Immunosuppression with a combination of the leflunomide analog, FK778, and microemulsified cyclosporine for renal transplantation in mongrel dogs |
| Q74686279 | Immunosuppressive agents: recent developments in molecular action and clinical application |
| Q44812518 | Impact of C2 measurement on cyclosporine Neoral dosing in a Latin-American transplant program: the Guatemalan experience |
| Q44256929 | Impact of cyclosporine dosing frequency on graft function and survival after the conversion from sandimmun to neoral in stable kidney transplanted patients |
| Q35710933 | Impact of cyclosporine on the development of immunosuppressive therapy. |
| Q59157789 | Influence of drug formulation on utilization and outcomes: Neoral and monitoring by sparse sample area under the curve |
| Q73166567 | Limited sampling strategies |
| Q74685641 | Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients |
| Q77175732 | Meeting the challenges of transplantation in the 21st century |
| Q33937533 | Methods for clinical monitoring of cyclosporin in transplant patients. |
| Q33920671 | Neoral absorption profiling: an evolution in effectiveness. |
| Q73544658 | Neoral dose monitoring with cyclosporine 2-hour postdose levels in heart transplant patients receiving anti-thymocyte globulin induction |
| Q44491040 | Neoral monitoring by limited sampling area under the concentration time curve in stable indian renal transplant recipients |
| Q34105942 | Neoral monitoring: limitations of trough level monitoring and the potential role of limited sampling strategies |
| Q33920645 | Neoral use in the liver transplant recipient |
| Q33920652 | Neoral use in the renal transplant recipient |
| Q77176336 | Neoral versus Sandimmun: clinical impact and modification of immunosuppressive therapy in cardiac transplantation |
| Q43672150 | Once-a-day oral dosing regimen of cyclosporin A: combined therapy of cyclosporin A premicroemulsion concentrates and enteric coated solid-state premicroemulsion concentrates |
| Q57703989 | Optimization of cyclosporine therapy in kidney transplantation |
| Q43828405 | Optimization of cyclosporine therapy in the Neoral era: abbreviated AUC, single blood sampling? |
| Q52237037 | Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997). |
| Q43828391 | Optimizing Neoral therapeutic drug monitoring with cyclosporine trough (C(0)) and C(2) concentrations in stable renal allograft recipients. |
| Q34610933 | Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I |
| Q83220048 | Pharmacokinetic profiling of cyclosporine microemulsion during the first 3 weeks after simultaneous pancreas-kidney transplantation |
| Q57703992 | Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients |
| Q43875081 | Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients |
| Q46830629 | Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients |
| Q41615861 | Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral |
| Q33636611 | Relationship of pharmacokinetics to clinical outcomes |
| Q41665587 | Relevance of pharmacokinetics in narrow therapeutic index drugs |
| Q38501680 | Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment |
| Q44570673 | Single daily dose administration of cyclosporine in renal transplant recipients |
| Q46742533 | Single daily dose administration of cyclosporine in renal transplant recipients: a preliminary report |
| Q57169662 | THE USE OF NEORAL IN RHEUMATOID ARTHRITIS |
| Q44577546 | Tacrolimus-Basiliximab versus Cyclosporine-Basiliximab in renal transplantation "de novo": acute rejection and complications. |
| Q43865665 | The area under the concentration-time curve versus trough and peak blood level monitoring in renal transplant recipients on cyclosporine |
| Q44812503 | The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2. |
| Q35711472 | The promise of C2, Simulect, and Certican in heart transplantation |
| Q77166098 | Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus |
| Q35711332 | Therapeutic drug monitoring of cyclosporine: 20 years of progress |
| Q34599623 | Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. |
| Q79819511 | Therapeutic monitoring of cyclosporine in kidney transplantation: the Halifax experience |
| Q33661554 | Therapeutic strategies for optimal use of novel immunosuppressants |
| Q44822760 | Two-hour post-dose cyclosporin A levels in adolescent renal transplant recipients in the late post-transplant period |
| Q79819453 | Use of cyclosporine in renal transplantation |
| Q51673782 | Validation of Sparse Sampling Strategies to Estimate Cyclosporine A Area Under the Concentration-Time Curve Using Either a Specific Radioimmunoassay or High-Performance Liquid Chromography Method |
| Q53935621 | Validity of open labeled versus blinded trials: a meta-analysis comparing Neoral and Sandimmune. |
| Q35025829 | What's in the pipeline? New immunosuppressive drugs in transplantation |
Search more.